Drug General Information
Drug ID
D01JFM
Former ID
DIB001402
Drug Name
AC-170
Drug Type
Small molecular drug
Indication Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10:C91.0, H10, H10.45, T78.4] Phase 3 [524743]
Company
Aciex Therapeutics Inc
Structure
Download
2D MOL

3D MOL

Formula
C6H6BrNO
Canonical SMILES
C1=CC(=NC=C1Br)CO
InChI
1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
InChIKey
RUCZFWMEACWFER-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [551442]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 524743ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health.
Ref 551442Clinical pipeline report, company report or official report of NicOx SA.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.